- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02622308
The Effects of INP on Peripheral Circulation in Dialysis Patients and Patients With PAD and Leg Ulcers
The Effects of Intermittent Negative Pressure on Peripheral Circulation in Dialysis Patients and Patients With Lower Limb Ischemia and Leg Ulcers
This experimental study will look at the effects of INP therapy for two patient groups: 1) patients with reduced peripheral circulation and chronic wounds in patients with renal disease (dialysis patients); 2) and peripheral arterial disease and leg ulcers. The project is designed as a non-randomized clinical trial with single-subject multiple baseline design. Also the intervention will be subjected on the same leg for each individual throughout the study period. The other leg will act as a control. A baseline measure with patient history collection will be performed before a four-week intervention period. These measures include: Segmental pulse-volume-recording, Segmental skin perfusion pressure with a laser Doppler sensor and a pressure cuff to evaluate reactive hyperemia (Sensilase, Väsamed) and a health survey (SF-12/EQ-5D-5L) or similar. After four weeks and eight weeks of intervention, the same tests will be repeated. A final follow-up test will be two weeks after cessation of the intermittent negative pressure intervention. The study will look at the effect of INP on renal failure patients who are given dialysis at a dialysis center located at Oslo University Hospital, Ullevål. Otivio AS has supplied the FlowOx devices and provided the necessary training to perform this project. Outcome variables assessed before, during and after the 10-week study period will be: wound healing, quality of life, skin perfusion pressure and segmental pulse-volume recording. The aim of this project is to prospectively examine and elucidate the effect of intermittent negative pressure therapy on clinically relevant measures related to the reduction of peripheral macro- and microcirculation in patients with renal failure undergoing dialysis treatment.
The hypothesis of the study is:
- Application of INP in patients with renal failure, by the use of the FlowOx™ device, will improve wound healing and peripheral circulation in the foot compared to before treatment (baseline) in patients undergoing dialysis treatment.
- Application of INP in patients with PAD, by the use of the FlowOx™ device, will improve macro- and microcirculation and wound healing in the foot compared to before treatment (baseline) in patients with chronic wounds.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Oslo, Norway
- Oslo University Hospital - Ullevål, Department of Nephrology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able and willing to provide informed consent
- Age: 18-96 years
- Affected foot/shoe size <46 (approximate foot length< 29,5 cm)
- Receiving hemodialysis ≥3 times per week for 1 hour per treatment OR
- Peripheral arterial disease and leg ulcer
Exclusion criteria:
- Incapable to consent voluntarily, i.e. patients who are not able to consent due to their mental status, or who are not willing or able to perform the negative pressure therapy in a sitting position
- Not adhering to the INP therapy program
- Patients with an expected life-span less than 3 months
- Patients in whom the remaining limb is non-functional, for example due to previous stroke
- Patients in which a deep venous thrombosis or pulmonary embolism is suspected
- Limbs with uncontrolled infection
- Previous lumbar sympathectomy
- Bilateral amputation of lower extremity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: single-case design
The study design will be a non-randomized clinical trial with single-subject baseline design (also called single-case baseline design) where each patients act as their own controls: Observations (A) will be taken before and after a 8-week intervention period. We plan to introduce a 4-week INP-treatment period ('FlowOx™) (B) using the same outcome variables that were used as baseline measures. If the patient demonstrates improvements in outcome variables after the first treatment period (B1), the patient will be asked to continue INP therapy for another 4-week period, before a final assessment after a total of 8-week intervention period (B2) (A-B-B design). |
FlowOx™ uses intermittent negative and atmospheric pressure, and is intended for use as an adjunct non-invasive therapy for the treatment of reduced peripheral circulation.
Negative pressure cycles are created by alternating between removing air and venting the vacuum-chamber to atmospheric pressure.
The vacuum cycle is controlled by the Control Unit (Pump).
FlowOx™ is designed to assists wound healing indirectly by improving blood flow to the affected limb and augmenting the wound healing effect of the contact dressings and any associated medication.
Treatment is planned to be applied while the participants are seated and it does not interfere with other activities normally enjoyed while seated.
Treatment is recommended for one to two hours per session aiming to improve blood flow in the affected area and thus the clinical outcomes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Segmental Skin Perfusion Pressure
Time Frame: 8 weeks
|
Fully automated and quantitative evaluation of microcirculatory perfusion in the skin of the foot and leg (Sensilase, Vasamed, USA). Multiple levels can be assessed on limbs; bilateral measurement helps to manage test time Not susceptible to interference effects from medial calcification Requires use of pressure cuffs to occlude blood flow for specified time period in order to evaluate reactive hyperemic response to controlled release of pressure Graphical output of pressure and perfusion during cuff deflation indicates the pressure (mmHg) at which skin perfusion is found to return in addition to pressure contour |
8 weeks
|
|
Life Quality (SF-12 or EQ-5D-5L)
Time Frame: 8 weeks
|
SF-12 or EQ-5D-5L
|
8 weeks
|
|
Pulse Volume Recording / segmental volume plethysmography (PVR)
Time Frame: 8 weeks
|
PVR shows variations in the volume of blood passing through a limb during each cardiac cycle. The instrument that will be used to measure PVR for this study is Sensilase (Vasamed, USA) OR MacroLab (STR Teknikk, strteknikk.no, Aalesund, Norway). Multiple levels can be assessed on limbs. The measures are not susceptible to interference effects from medial calcification. |
8 weeks
|
|
Wound healing (Measuring wound diameter and length)
Time Frame: 8 weeks
|
Measurement of healing to provide a means by which progress over time to wound closure can be identified.
A wound nurse will take pictures at study start and at follow-up.
|
8 weeks
|
|
Ankle-Brachial Pressure Index (ABPI)
Time Frame: 8 weeks
|
The ratio of the blood pressure at the ankle (dorsal pedis artery/posterior tibial artery) to the blood pressure in the upper arm (brachial artery)
|
8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jonny Hisdal, PhD, Oslo University Hospital - Aker
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015/1318
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
Marissa JarosinskiTerminatedPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
OrbusNeichEucatech AG; Centre Européen de Recherche CardiovasculaireRecruitingPeripheral Arterial Disease | Peripheral Arterial Occlusive DiseaseSpain, Singapore, Belgium, Germany
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
BayerCompleted
-
Wroclaw Medical UniversityPoznan University of Medical Sciences; Military Institute of Medicine National...RecruitingPeripheral Arterial Disease(PAD)Poland
-
University of NebraskaRecruitingPeripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Peripheral Artery Occlusive DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
Clinical Trials on FlowOx™
-
Otivio ASHannover Medical School; mediq Innovation Experts GmbHTerminatedIntermittent Claudication | Peripheral Vascular Disease | Ischemia Limb | Critical Limb Ischemia | Walking, DifficultyGermany
-
Otivio ASHaukeland University HospitalRecruitingPain | Multiple Sclerosis | Spasticity, MuscleNorway
-
Oslo University HospitalOtivio ASCompletedPeripheral Arterial Disease | Intermittent ClaudicationNorway
-
Oslo University HospitalOtivio ASCompletedWound Healing, Leg and Foot Ulcers, Macrocirculation, MicrocirculationNorway
-
Otivio ASEnrolling by invitationPain | Multiple Sclerosis | Spasticity, MuscleNorway
-
Lo Zhiwen JosephOtivio ASRecruitingDiabetic Foot UlcerSingapore
-
Otivio ASThe Research Council of Norway; European UnionUnknownPeriferal Arterial Occlusive Disease, PAODNorway
-
Otivio ASActive, not recruitingMultiple Sclerosis | Spasticity, Muscle | Pain, ChronicSweden
-
BaroNova, Inc.Completed
-
London Health Sciences CentreUniversity of Western Ontario, Canada; Synaptive MedicalUnknownBrain Damage, Chronic | Cerebellar Cognitive Affective Syndrome | Cerebellar Mutism